Top

Published in:

Open Access 01-10-2018 | Original Contribution

Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells

Published in: European Journal of Nutrition | Issue 7/2018

Abstract

Purpose

Human melanoma is a highly aggressive incurable cancer due to intrinsic cellular resistance to apoptosis, reprogramming, proliferation and survival during tumour progression. Sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, plays a role in carcinogenesis in many cancer types. However, the cytotoxic molecular mechanisms and gene expression profiles promoted by SFN in human melanoma remain unknown.

Methods

Three different cell lines were used: two human melanoma A375 and 501MEL and human epidermal melanocytes (HEMa). Cell viability and proliferation, cell cycle analysis, cell migration and invasion and protein expression and phosphorylation status of Akt and p53 upon SFN treatment were determined. RNA-seq of A375 was performed at different time points after SFN treatment.

Results

We demonstrated that SFN strongly decreased cell viability and proliferation, induced G₂/M cell cycle arrest, promoted apoptosis through the activation of caspases 3, 8, 9 and hampered migration and invasion abilities in the melanoma cell lines. Remarkably, HEMa cells were not affected by SFN treatment. Transcriptomic analysis revealed regulation of genes involved in response to stress, apoptosis/cell death and metabolic processes. SFN upregulated the expression of pro-apoptotic genes, such as p53, BAX, PUMA, FAS and MDM2; promoted cell cycle inhibition and growth arrest by upregulating EGR1, GADD45B, ATF3 and CDKN1A; and simultaneously acted as a potent inhibitor of genotoxicity by launching the stress-inducible protein network (HMOX1, HSPA1A, HSPA6, SOD1).

Conclusion

Overall, the data show that SFN cytotoxicity in melanoma derives from complex and concurrent mechanisms during carcinogenesis, which makes it a promising cancer prevention agent.

Available only for authorised users

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. doi:10.1200/jco.2009.23.4799 CrossRefPubMedPubMedCentral

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289. doi:10.3322/caac.21349 CrossRefPubMed

Bhatia P, Friedlander P, Zakaria EA, Kandil E (2015) Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med 3(2):24. doi:10.3978/j.issn.2305-5839.2014.12.05 CrossRefPubMedPubMedCentral

Herzberg B, Fisher DE (2016) Metastatic melanoma and immunotherapy. Clin Immunol 172:105–110CrossRefPubMedPubMedCentral

Olszanski AJ (2014) Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm 20(4):346–356. doi:10.18553/jmcp.2014.20.4.346 CrossRefPubMed

Cheung KL, Kong AN (2010) Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 12(1):87–97. doi:10.1208/s12248-009-9162-8 CrossRefPubMed

Shu L, Cheung KL, Khor TO, Chen C, Kong AN (2010) Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev 29(3):483–502. doi:10.1007/s10555-010-9239-y CrossRefPubMed

Fimognari C, Hrelia P (2007) Sulforaphane as a promising molecule for fighting cancer. Mutat Res 635(2–3):90–104. doi:10.1016/j.mrrev.2006.10.004 CrossRefPubMed

Juge N, Mithen RF, Traka M (2007) Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64(9):1105–1127. doi:10.1007/s00018-007-6484-5 CrossRefPubMed

10.

Powolny AA, Bommareddy A, Hahm ER, Normolle DP, Beumer JH, Nelson JB, Singh SV (2011) Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst 103(7):571–584. doi:10.1093/jnci/djr029 CrossRefPubMedPubMedCentral

11.

Misiewicz I, Skupinska K, Kowalska E, Lubinski J, Kasprzycka-Guttman T (2004) Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NAD(P)H: quinone reductase and apoptosis in human lymphoblastoid cells. Acta Biochim Pol 51(3):711–721PubMed

12.

Prawan A, Kundu JK, Surh YJ (2005) Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid Redox Signal 7(11–12):1688–1703. doi:10.1089/ars.2005.7.1688 CrossRefPubMed

13.

Fahey JW, Talalay P (1999) Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 37(9–10):973–979CrossRefPubMed

14.

Mithen R, Faulkner K, Magrath R, Rose P, Williamson G, Marquez J (2003) Development of isothiocyanate-enriched broccoli, and its enhanced ability to induce phase 2 detoxification enzymes in mammalian cells. Theor Appl Genet 106(4):727–734. doi:10.1007/s00122-002-1123-x CrossRefPubMed

15.

Bao Y, Wang W, Zhou Z, Sun C (2014) Benefits and risks of the hormetic effects of dietary isothiocyanates on cancer prevention. PLoS ONE 9(12):e114764. doi:10.1371/journal.pone.0114764 CrossRefPubMedPubMedCentral

16.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S (2015) Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol 35(Suppl):S25–S54. doi:10.1016/j.semcancer.2015.02.006 CrossRefPubMedPubMedCentral

17.

Sestili P, Fimognari C (2015) Cytotoxic and antitumor activity of sulforaphane: the role of reactive oxygen species. Biomed Res Int 2015:402386. doi:10.1155/2015/402386 CrossRefPubMedPubMedCentral

18.

Gamet-Payrastre L, Li P, Lumeau S, Cassar G, Dupont MA, Chevolleau S, Gasc N, Tulliez J, Terce F (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 60(5):1426–1433PubMed

19.

Mondal A, Biswas R, Rhee YH, Kim J, Ahn JC (2016) Sulforaphene promotes Bax/Bcl2, MAPK-dependent human gastric cancer AGS cells apoptosis and inhibits migration via EGFR, p-ERK1/2 down-regulation. Gen Physiol Biophys 35(1):25–34. doi:10.4149/gpb_2015033 CrossRefPubMed

20.

Wang L, Tian Z, Yang Q, Li H, Guan H, Shi B, Hou P, Ji M (2015) Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget 6(28):25917–25931. doi:10.18632/oncotarget.4542 CrossRefPubMedPubMedCentral

21.

Kim SJ, Kim BS, Kyung TW, Lee SC, Rho CW, Choi KR, Hwang HJ, Choi HS (2006) Suppressive effects of young radish cultivated with sulfur on growth and metastasis of B16-F10 melanoma cells. Arch Pharm Res 29(3):235–240CrossRefPubMed

22.

Thejass P, Kuttan G (2006) Antimetastatic activity of sulforaphane. Life Sci 78(26):3043–3050. doi:10.1016/j.lfs.2005.12.038 CrossRefPubMed

23.

Thejass P, Kuttan G (2007) Modulation of cell-mediated immune response in B16F-10 melanoma-induced metastatic tumor-bearing C57BL/6 mice by sulforaphane. Immunopharmacol Immunotoxicol 29(2):173–186. doi:10.1080/08923970701511728 CrossRefPubMed

24.

Hamsa TP, Thejass P, Kuttan G (2011) Induction of apoptosis by sulforaphane in highly metastatic B16F-10 melanoma cells. Drug Chem Toxicol 34(3):332–340. doi:10.3109/01480545.2010.538694 CrossRefPubMed

25.

Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C (2015) STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43(Database issue):D447–D452. doi:10.1093/nar/gku1003 CrossRefPubMed

26.

Sankpal UT, Goodison S, Abdelrahim M, Basha R (2011) Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem 7(5):518–525CrossRefPubMed

27.

Stoy C, Sundaram A, Rios Garcia M, Wang X, Seibert O, Zota A, Wendler S, Mannle D, Hinz U, Sticht C, Muciek M, Gretz N, Rose AJ, Greiner V, Hofmann TG, Bauer A, Hoheisel J, Berriel Diaz M, Gaida MM, Werner J, Schafmeier T, Strobel O, Herzig S (2015) Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. EMBO Mol Med 7(8):1048–1062. doi:10.15252/emmm.201404837 CrossRefPubMedPubMedCentral

28.

Clarke JD, Dashwood RH, Ho E (2008) Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 269(2):291–304. doi:10.1016/j.canlet.2008.04.018 CrossRefPubMedPubMedCentral

29.

Cornblatt BS, Ye L, Dinkova-Kostova AT, Erb M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani P, Davidson NE, Talalay P, Kensler TW, Visvanathan K (2007) Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 28(7):1485–1490. doi:10.1093/carcin/bgm049 CrossRefPubMed

30.

Moon D-O, Kim M-O, Kang S-H, Choi YH, Kim G-Y (2009) Sulforaphane suppresses TNF-α-mediated activation of NF-κB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett 274(1):132–142. doi:10.1016/j.canlet.2008.09.013 CrossRefPubMed

31.

Park SY, Kim GY, Bae SJ, Yoo YH, Choi YH (2007) Induction of apoptosis by isothiocyanate sulforaphane in human cervical carcinoma HeLa and hepatocarcinoma HepG2 cells through activation of caspase-3. Oncol Rep 18(1):181–187PubMed

32.

Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD (2012) Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS ONE 7(12):e51251. doi:10.1371/journal.pone.0051251 CrossRefPubMedPubMedCentral

33.

Tseng E, Scott-Ramsay EA, Morris ME (2004) Dietary organic isothiocyanates are cytotoxic in human breast cancer MCF-7 and mammary epithelial MCF-12A cell lines. Exp Biol Med (Maywood) 229(8):835–842CrossRef

34.

Mantso T, Sfakianos AP, Atkinson A, Anestopoulos I, Mitsiogianni M, Botaitis S, Perente S, Simopoulos C, Vasileiadis S, Franco R, Pappa A, Panayiotidis MI (2016) Development of a novel experimental in vitro model of isothiocyanate-induced apoptosis in human malignant melanoma cells. Anticancer Res 36(12):6303–6309CrossRefPubMed

35.

Fisher ML, Adhikary G, Grun D, Kaetzel DM, Eckert RL (2015) The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Mol Carcinog. doi:10.1002/mc.22448 CrossRefPubMedPubMedCentral

36.

Rudolf K, Cervinka M, Rudolf E (2014) Sulforaphane-induced apoptosis involves p53 and p38 in melanoma cells. Apoptosis 19(4):734–747. doi:10.1007/s10495-013-0959-7 CrossRefPubMed

37.

Yao A, Shen Y, Wang A, Chen S, Zhang H, Chen F, Chen Z, Wei H, Zou Z, Shan Y, Zhang X (2015) Sulforaphane induces apoptosis in adipocytes via Akt/p70s6k1/Bad inhibition and ERK activation. Biochem Biophys Res Commun 465(4):696–701. doi:10.1016/j.bbrc.2015.08.049 CrossRefPubMed

38.

Zhang Z, Li C, Shang L, Zhang Y, Zou R, Zhan Y, Bi B (2016) Sulforaphane induces apoptosis and inhibits invasion in U251MG glioblastoma cells. Springerplus 5:235. doi:10.1186/s40064-016-1910-5 CrossRefPubMedPubMedCentral

39.

Zuryn A, Litwiniec A, Safiejko-Mroczka B, Klimaszewska-Wisniewska A, Gagat M, Krajewski A, Gackowska L, Grzanka D (2016) The effect of sulforaphane on the cell cycle, apoptosis and expression of cyclin D1 and p21 in the A549 non-small cell lung cancer cell line. Int J Oncol 48(6):2521–2533. doi:10.3892/ijo.2016.3444 CrossRefPubMed

40.

Jackson SJ, Singletary KW (2004) Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. J Nutr 134(9):2229–2236CrossRefPubMed

41.

Liu KC, Shih TY, Kuo CL, Ma YS, Yang JL, Wu PP, Huang YP, Lai KC, Chung JG (2016) Sulforaphane induces cell death through G2/M phase arrest and triggers apoptosis in HCT 116 human colon cancer cells. Am J Chin Med 44(6):1289–1310. doi:10.1142/s0192415x16500725 CrossRefPubMed

42.

Porter LA, Singh G, Lee JM (2000) Abundance of cyclin B1 regulates gamma-radiation-induced apoptosis. Blood 95(8):2645–2650PubMed

43.

Shih RS, Wong SH, Schoene NW, Zhang JJ, Lei KY (2010) Enhanced Gadd45 expression and delayed G2/M progression are p53-dependent in zinc-supplemented human bronchial epithelial cells. Exp Biol Med (Maywood) 235(8):932–940. doi:10.1258/ebm.2010.010076 CrossRef

44.

Toyoshima FMT, Wada A, Fukuda M, Nishida E (1998) Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J 17(10):2728–2735. doi:10.1093/emboj/17.10.2728 (T1998) CrossRefPubMedPubMedCentral

45.

Lee YR, Noh EM, Han JH, Kim JM, Hwang BM, Kim BS, Lee SH, Jung SH, Youn HJ, Chung EY, Kim JS (2013) Sulforaphane controls TPA-induced MMP-9 expression through the NF-kappaB signaling pathway, but not AP-1, in MCF-7 breast cancer cells. BMB Rep 46(4):201–206CrossRefPubMedPubMedCentral

46.

Lenzi M, Fimognari C, Hrelia P (2014) Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res 159:207–223. doi:10.1007/978-3-642-38007-5_12 CrossRefPubMed

47.

Shan Y, Zhang L, Bao Y, Li B, He C, Gao M, Feng X, Xu W, Zhang X, Wang S (2013) Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem 24(6):1062–1069. doi:10.1016/j.jnutbio.2012.08.004 CrossRefPubMed

48.

Gerhauser C, You M, Liu J, Moriarty RM, Hawthorne M, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res 57(2):272–278PubMed

49.

Greaney AJ, Maier NK, Leppla SH, Moayeri M (2016) Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J Leukoc Biol 99(1):189–199. doi:10.1189/jlb.3A0415-155RR CrossRefPubMed

50.

Salvador JM, Brown-Clay JD, Fornace AJ Jr (2013) Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv Exp Med Biol 793:1–19. doi:10.1007/978-1-4614-8289-5_1 CrossRefPubMed

51.

Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H, Zhu X, Mazzacurati L, Li X, Petrik KL, Fornace AJ Jr, Rajasekaran B, Zhan Q (2002) ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 21(49):7488–7496. doi:10.1038/sj.onc.1205896 CrossRefPubMed

52.

Huang X, Li X, Guo B (2008) KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 283(44):29795–29801. doi:10.1074/jbc.M802515200 CrossRefPubMedPubMedCentral

53.

Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA (2009) Adenosine receptors and cancer. Handb Exp Pharmacol 193:399–441. doi:10.1007/978-3-540-89615-9_14 CrossRef

54.

Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ (2001) Physical interaction between p53 and primary response gene Egr-1. Int J Oncol 18(4):863–870PubMed

55.

Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM (1997) Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 272(32):20131–20138CrossRefPubMed

56.

Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I (2001) The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3(12):1124–1128. doi:10.1038/ncb1201-1124 CrossRefPubMed

57.

Yang M, Teng W, Qu Y, Wang H, Yuan Q (2016) Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1. Breast Cancer Res Treat 158(2):277–286. doi:10.1007/s10549-016-3888-7 CrossRefPubMed

58.

Guo B, Cao S, Toth K, Azrak RG, Rustum YM (2000) Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 6(2):718–724PubMed

59.

Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80(2):293–299CrossRefPubMed

60.

Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188(11):2033–2045CrossRefPubMedPubMedCentral

61.

Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7(3):683–694CrossRefPubMed

62.

Choi S, Singh SV (2005) Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 65(5):2035–2043. doi:10.1158/0008-5472.can-04-3616 CrossRefPubMed

63.

Chu WF, Wu DM, Liu W, Wu LJ, Li DZ, Xu DY, Wang XF (2009) Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. Oral Oncol 45(11):998–1004. doi:10.1016/j.oraloncology.2009.05.641 CrossRefPubMed

64.

Fimognari C, Nusse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P (2002) Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis 23(4):581–586CrossRefPubMed

65.

Shang HS, Shih YL, Lee CH, Hsueh SC, Liu JY, Liao NC, Chen YL, Huang YP, Lu HF, Chung JG (2016) Sulforaphane-induced apoptosis in human leukemia HL-60 cells through extrinsic and intrinsic signal pathways and altering associated genes expression assayed by cDNA microarray. Environ Toxicol. doi:10.1002/tox.22237 CrossRefPubMed

66.

Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, Herman-Antosiewicz A (2005) Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 280(20):19911–19924. doi:10.1074/jbc.M412443200 CrossRefPubMed

67.

Chien J, Campioni M, Shridhar V, Baldi A (2009) HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets 9(4):451–468CrossRefPubMedPubMedCentral

68.

Lu P, Takai K, Weaver VM, Werb Z (2011) Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a005058 CrossRefPubMedPubMedCentral

69.

Heinz M, Niederleithner HL, Puujalka E, Soler-Cardona A, Grusch M, Pehamberger H, Loewe R, Petzelbauer P (2015) Activin A is anti-lymphangiogenic in a melanoma mouse model. J Invest Dermatol 135(1):212–221. doi:10.1038/jid.2014.328 CrossRefPubMed

70.

Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li WJ, Tuan RS, Deyrup AT, Khanna C, Helman L (2009) Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. Oncogene 28(38):3401–3411. doi:10.1038/onc.2009.206 CrossRefPubMedPubMedCentral

71.

Zhang X, Rozengurt E, Reed EF (2010) HLA class I molecules partner with integrin beta4 to stimulate endothelial cell proliferation and migration. Sci Signal 3(149):ra85. doi:10.1126/scisignal.2001158 CrossRefPubMed

72.

Zhang Z, Atwell LL, Farris PE, Ho E, Shannon J (2016) Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies. Public Health Nutr 19(7):1288–1295. doi:10.1017/S136898001500244X CrossRefPubMed

73.

Alumkal JJ, Slottke R, Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW, Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt R, Mori M (2015) A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs 33(2):480–489. doi:10.1007/s10637-014-0189-z CrossRefPubMed

74.

Wu QJ, Yang Y, Vogtmann E, Wang J, Han LH, Li HL, Xiang YB (2013) Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol 24(4):1079–1087. doi:10.1093/annonc/mds601 CrossRefPubMed

75.

Vyas AR, Moura MB, Hahm ER, Singh KB, Singh SV (2016) Sulforaphane inhibits c-Myc-mediated prostate cancer stem-like traits. J Cell Biochem 117(11):2482–2495. doi:10.1002/jcb.25541 CrossRefPubMedPubMedCentral

76.

Islam SS, Mokhtari RB, Akbari P, Hatina J, Yeger H, Farhat WA (2016) Simultaneous targeting of bladder tumor growth, survival, and epithelial-to-mesenchymal transition with a novel therapeutic combination of acetazolamide (AZ) and sulforaphane (SFN). Target Oncol 11(2):209–227. doi:10.1007/s11523-015-0386-5 CrossRefPubMed

77.

Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Buchler MW, Salnikov AV, Herr I (2011) Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther 19(1):188–195. doi:10.1038/mt.2010.216 CrossRefPubMed

78.

Mokhtari RB, Kumar S, Islam SS, Yazdanpanah M, Adeli K, Cutz E, Yeger H (2013) Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines. BMC Cancer 13:378. doi:10.1186/1471-2407-13-378 CrossRefPubMedPubMedCentral

79.

Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P (2006) Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 55(1):53–62. doi:10.1207/s15327914nc5501_7 CrossRefPubMed

Title: Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells
Publication date: 01-10-2018
Published in: European Journal of Nutrition / Issue 7/2018
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-017-1527-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antitumor activity and expression profiles of genes induced by sulforaphane in human melanoma cells

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Micronutrient intake adequacy and depression risk in the SUN cohort study

l-Arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats by normalizing plasma nitric oxide concentration and increasing plasma agmatine concentration

Dietary patterns and changes in frailty status: the Rotterdam study

IL-10 and TGF-β unbalanced levels in neutrophils contribute to increase inflammatory cytokine expression in childhood obesity

Nut intake and 5-year changes in body weight and obesity risk in adults: results from the EPIC-PANACEA study

Supplement intervention associated with nutritional deficiencies in autism spectrum disorders: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page